Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

John D. Hainsworth, Fonda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, and Razelle Kurzrock

ABSTRACT

Purpose
Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer. These molecular alterations may occur in other tumor types for which the efficacy of targeted therapy remains unclear. The MyPathway study evaluates the efficacy and safety of selected targeted therapies in tumor types that harbor relevant genetic alterations but are outside of current labeling for these treatments.

Methods
MyPathway (ClinicalTrials.gov identifier: NCT02091141) is a multicenter, nonrandomized, phase IIa multiple basket study. Patients with advanced refractory solid tumors harboring molecular alterations in human epidermal growth factor receptor-2, epidermal growth factor receptor, v-raf murine sarcoma viral oncogene homolog B1, or the Hedgehog pathway are treated with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. The primary end point is investigator-assessed objective response rate within each tumor-pathway cohort.

Results
Between April 1, 2014 and November 1, 2016, 251 patients with 35 different tumor types received study treatment. The efficacy population contains 230 treated patients who were evaluated for response or discontinued treatment before evaluation. Fifty-two patients (23%) with 14 different tumor types had objective responses (complete, n = 4; partial, n = 48). Tumor-pathway cohorts with notable objective response rates included human epidermal growth factor receptor-2–amplified/overexpressing colorectal (38% [14 of 37]; 95% CI, 23% to 55%) and v-raf murine sarcoma viral oncogene homolog B1, or the Hedgehog pathway are treated with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. The primary end point is investigator-assessed objective response rate within each tumor-pathway cohort.

Conclusion
The four currently approved targeted therapy regimens in the MyPathway study produced meaningful responses when administered without chemotherapy in several refractory solid tumor types not currently labeled for these agents.

INTRODUCTION

Molecular profiling is routinely used to guide the selection of targeted therapies for the treatment of patients with lung, breast, colon, and other types of cancer. When used in molecularly identified patients with indicated tumor types, agents targeting human epidermal growth factor receptor-2 (HER2),1 epidermal growth factor receptor (EGFR),2 v-raf murine sarcoma viral oncogene homolog B1 (BRAF),3 and the Hedgehog pathway4 have been among the most effective therapies introduced during the last 20 years. Molecular alterations in these genes and pathways also occur in a variety of nonindicated tumor types. The low incidence of the targeted molecular alterations in these tumor types (usually < 5%) has made it difficult to recruit sufficient numbers of patients into traditional drug development studies, although activity has been documented in anecdotal reports.5–12 Basket studies provide the opportunity to evaluate the efficacy of targeted therapies in patient populations defined by the presence of specific molecular tumor abnormalities, rather than by primary site or tumor histology.13,14 Results of
several small basket studies have recently been reported. In one such study (ClinicalTrials.gov identifier: NCT01524978), treatment with vemurafenib produced responses in 24 of 95 patients (25%) with BRAF V600-mutated tumor types other than melanoma and colorectal cancer.\textsuperscript{15} Such data suggest that certain molecular alterations are important in determining the response to targeted treatment, independent of tumor type.\textsuperscript{15} However, multiple variables influence the efficacy of targeted therapy, including the biology and relevance of the target, the mechanism of target inhibition, the tumor type, the presence of other molecular alterations, and the therapy selected.

MyPathway is an ongoing, multicenter, phase IIa study that combines multiple basket studies under an adaptable master protocol. The objective of the study is to evaluate the efficacy of treatments targeting molecular alterations in HER2 (pertuzumab plus trastuzumab), BRAF (vemurafenib), Hedgehog pathway (vismodegib), or EGFR (erlotinib) in patients with tumor types outside of current labeling for these treatment regimens. In this report, we summarize the efficacy results in the first 230 treated patients who were efficacy evaluable.

### METHODS

**Patients**

Eligible patients are required to have refractory, metastatic solid tumors containing targetable, pathway-activating, molecular alterations in HER2, EGFR, BRAF, or the Hedgehog pathway. Molecular profiling was not conducted as part of this study; rather, eligible patients were required to have previous profiling demonstrating one of the target alterations. Molecular testing by various local Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories was acceptable in this study. Molecular profiling must have been performed on tissue obtained at the most recent tumor biopsy.

Additional eligibility requirements include measurable or evaluable lesions\textsuperscript{17} and an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2. Patients with tumor types for which the study treatments are approved or in active development are not eligible. Specific tumor mutations with evidence suggesting inactivity of the study drugs are also ineligible. All patients also need to fulfill additional eligibility criteria pertinent to the specific therapeutic agents (Data Supplement).

Molecular alterations eligible for MyPathway as well as required testing methods are detailed in Table 1. Tumors with HER2 amplification, overexpression, and/or activating mutations were eligible. For EGFR and BRAF, known or putative activating mutations were required. Eligible Hedgehog pathway alterations included gain-of-function mutations of Smoothened (SMO) or loss-of-function mutations of Patched Homolog-1 (PTCH-1). Unusual mutations considered possible activating mutations for any of the pathways (or loss of function mutations for PTCH-1) were permitted if previously reported in at least two unique specimens in the Catalogue of Somatic Mutations in Cancer database.\textsuperscript{6}

The above protocol-specified molecular alterations were identified through local CLIA-approved laboratory reports and reviewed by the study medical monitor for eligibility. For unusual molecular alterations, the medical monitor consulted appropriate members of the MyPathway Steering Committee regarding eligibility. Scanned laboratory reports are kept in a separate database from clinical trial data.

### Trial Design

MyPathway (ClinicalTrials.gov identifier: NCT02091141) is a multicenter, nonrandomized, open-label, multiple basket phase IIa trial (Fig 1). Eligible patients are assigned to a specific treatment cohort on the basis of the presence of a relevant target molecular alteration in their tumor biopsy.\textsuperscript{16} Patients with two or more study-eligible alterations may be treated for the alteration that the investigator considers most clinically relevant and may subsequently enter a different treatment cohort if they remain eligible.

Dosages of study treatments are in accordance with the United States package inserts for each product\textsuperscript{20-24} and are administered without systemic chemotherapy. Patients with HER2 molecular alterations are treated with intravenous pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) plus intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks). Patients with EGFR-activating mutations are treated with erlotinib (150 mg orally once daily). Patients with BRAF mutations are administered vemurafenib (960 mg orally twice daily), and those with Hedgehog pathway alterations receive vismodegib (150 mg orally once daily). Patients receive treatment of two cycles (6 weeks for pertuzumab plus trastuzumab; 8 weeks for all oral agents) and are then evaluated for response. Patients with objective response or stable disease (SD) continue therapy, with repeat evaluations every two cycles for the first 24 weeks, followed by evaluations every 12 weeks, until tumor progression, unacceptable toxicity, or other discontinuation criteria are met.

### Study End Points

The primary efficacy end point for MyPathway is the objective response rate (ORR). Responses are assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\textsuperscript{17} Confirmation of response (per RECIST) is not required. Secondary efficacy end points include duration of response (DOR), progression-free survival, and 1-year overall survival. DOR is measured from the date of first documentation of an objective response to the date of tumor progression/death or death due to any cause.
the last tumor assessment (if there was no progressive disease or death). Efficacy end points are evaluated separately for each tumor-pathway cohort, as defined by specific tumor type and molecular alteration.

**Statistical Analysis**

Analyses of ORR were performed in the efficacy analysis population, which included patients with measurable disease who were treated and had been evaluated for tumor response or who had been discontinued from treatment for any reason before the first response evaluation. Analyses of the DOR include the efficacy analysis patients who had objective responses. The data cutoff date for this interim efficacy analysis population was November 1, 2016.

ORRs were calculated for each tumor-pathway cohort. The 95% CIs of ORR were constructed using exact binomial distribution (Clopper-Pearson estimation method). The Kaplan-Meier approach was used to estimate median DORs and their 95% CIs and median follow-up duration.

For each tumor-pathway cohort, Simon’s two-stage design was used to make a preliminary assessment of treatment activity. For treatment-resistant tumor types (eg, non–small-cell lung cancer [NSCLC] and biliary), at least one response in the first 12 patients was required for cohort expansion; otherwise, the cohort was closed for futility (testing hypothesis: ORR, 5% v 20% at 10% one-sided type I error, 80% power). The MyPathway Steering Committee was consulted to determine treatment-resistant tumor types. For less-resistant tumor types (eg, colorectal, ovary), at least two responses in the first 13 patients were required for cohort expansion (testing hypothesis: ORR, 10% v 25% at 10% one-sided type I error, 80% power). If preliminary activity was demonstrated, accrual to the cohort continued to a maximum of 75 patients.

The initial study protocol did not include formal plans for separate analyses of cohorts with HER2 amplification/overexpression and HER2 mutation. However, apparent differences in tumor types and accrual of adequate numbers for analysis in each group led us to consider them separately. Similar considerations led to the separate analyses of groups with BRAF V600E mutations versus other BRAF mutations.

**RESULTS**

**Patients**

From April 1, 2014 to November 1, 2016, 251 patients with 35 different tumor types were enrolled from 38 centers in the United States.
States. The efficacy analysis population includes 230 patients; the remaining 21 patients had not yet reached the first efficacy evaluation. Patient demographics for the efficacy analysis group included: median age 62 years (range, 23 to 86 years), 51.0% male, 91.6% good performance status (Eastern Cooperative Oncology Group 0 or 1), and a median of 2.5 prior systemic treatment regimens (range, 0 to 9). In 107 patients, molecular alterations were detected in tumor tissue obtained at the time of diagnosis (primary site, n = 66; metastatic site, n = 37; unknown site, n = 4), whereas 123 patients had alterations detected in subsequent biopsies. Table 2 lists the tumor types and molecular alterations.

Tumor molecular alterations identified in the 230 patients were as follows: HER2, 151 (66%); BRAF, 49 (21%); Hedgehog, 21 (9%); and EGFR, nine (4%). Of the 151 patients enrolled in the HER2 arm, 114 exhibited HER2 amplification/overexpression (12 of whom also had HER2 mutations), 36 had HER2-activating mutations (without amplification detected by next-generation sequencing), and one had an RBMS-NRG1 fusion (an alteration suggested to result in HER2 pathway activation). Twenty-six of the 49 patients with BRAF-mutated tumors had V600E mutations, whereas 23 patients had tumors with a variety of other BRAF-activating mutations.

### Efficacy

The median duration of follow-up for the efficacy population was 9.7 months (range, 0.3 to 22.1 months). Fifty-two patients (23%) with 14 tumor types had objective responses (four complete responses [CR], 48 partial responses [PR]), and 52 additional patients had SD for >120 days. Responses were seen with each of the four targeted treatments.

Four tumor-pathway cohorts have enrolled at least 12 patients and had protocol-mandated efficacy review: HER2 amplified/overexpressing colorectal cancer (n = 37), HER2 amplified/overexpressing NSCLC (n = 16), HER2-mutated NSCLC (n = 14), and BRAF V600E-mutated NSCLC (n = 14). All four cohorts exceeded minimum efficacy criteria, and accrual has been extended. Several other cohorts have shown evidence of activity but have not reached the size for formal review. No tumor-pathway cohorts have been closed for lack of efficacy. However, the study was closed to further accrual of BRAF non-V600 mutations because of the low response rate (one of 23; 4%) in diverse tumor types.

### Patients With HER2 Amplification/Overexpression

Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). Objective responses were seen in nine primary tumor types: colorectal, bladder, biliary, salivary gland, NSCLC, pancreas, ovary, prostate, and skin (apocrine; Table 3).

Patients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD >120 days. The median DOR was 11 months (range, <1 to 16+ months; 95% CI, 2.8 months to not estimable).

Although the other tumor-pathway cohorts are relatively small, treatment with trastuzumab plus pertuzumab showed substantial activity in several other refractory tumor types. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD >120 days (Fig 2B). Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer had PR, and three had SD >120 days (Fig 2C). Finally, four of five patients with salivary gland carcinomas (80%; 95% CI, 28% to >99%) had responses (all PR).

### Table 2. Tumor Types and Molecular Alterations

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>HER2</th>
<th>BRAF</th>
<th>Hedgehog Pathway</th>
<th>EGFR</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung, non–small-cell</td>
<td>30</td>
<td>21</td>
<td>3</td>
<td>0</td>
<td>54</td>
</tr>
<tr>
<td>Colorectal</td>
<td>40</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>42</td>
</tr>
<tr>
<td>Biliary</td>
<td>11†</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Ovary</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Bladder</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>Uterus</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Breast</td>
<td>2†</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Small intestine</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Prostate</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Other (21 tumor types)</td>
<td>20</td>
<td>9</td>
<td>10</td>
<td>5</td>
<td>44</td>
</tr>
<tr>
<td>Total</td>
<td>151</td>
<td>49</td>
<td>21 (139)</td>
<td>9 (49)</td>
<td>230</td>
</tr>
</tbody>
</table>

NOTE. N = 230. Abbreviations: BRAF, murine sarcoma viral (v-raf) oncogene homolog B1; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor-2.

†One patient had a tumor with an RBMS-NRG1 fusion.

### Table 3. Efficacy of Treatment With Trastuzumab Plus Pertuzumab in Patients With HER2 Amplification/Overexpression

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>No. of Patients</th>
<th>Response, No. (%)</th>
<th>CR</th>
<th>PR</th>
<th>SD &gt; 120 Days</th>
<th>ORR, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>37</td>
<td>14 (38)</td>
<td>4</td>
<td>11</td>
<td></td>
<td>38 (23 to 55)</td>
</tr>
<tr>
<td>Bladder</td>
<td>16</td>
<td>2 (13)</td>
<td>2</td>
<td>12</td>
<td></td>
<td>13 (2 to 38)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9</td>
<td>2 (22)</td>
<td>2</td>
<td>22</td>
<td></td>
<td>33 (8 to 70)</td>
</tr>
<tr>
<td>Biliary</td>
<td>7</td>
<td>2 (29)</td>
<td>3</td>
<td>38</td>
<td></td>
<td>29 (4 to 71)</td>
</tr>
<tr>
<td>Ovary</td>
<td>8</td>
<td>1 (13)</td>
<td>0</td>
<td>6</td>
<td></td>
<td>13 (0 to 33)</td>
</tr>
<tr>
<td>Uterus</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>5</td>
<td>4 (80)</td>
<td>0</td>
<td>0</td>
<td></td>
<td>80 (28 to &gt;99)</td>
</tr>
<tr>
<td>Other (11 sites)*</td>
<td>16</td>
<td>1 (6)</td>
<td>1</td>
<td>6</td>
<td>3 (19)</td>
<td>13 (2 to 38)</td>
</tr>
<tr>
<td>Total</td>
<td>114</td>
<td>2 (28)</td>
<td>16</td>
<td>14</td>
<td></td>
<td>26 (19 to 35)</td>
</tr>
</tbody>
</table>

NOTE. N = 114. Includes 12 patients with amplification/overexpression plus mutation. Abbreviations: CR, complete response; ORR, objective response rate; PR, partial response; SD, stable disease.

*Responses occurred in patients with adenocarcinomas of the prostate (one) and skin (apocrine; one).
Patients With HER2 Mutation

Thirty-six patients received treatment with trastuzumab plus pertuzumab for tumors with HER2 mutations (without amplification/overexpression); four of these patients (11%; 95% CI, 3% to 26%) had objective responses. Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD at 120 days. Only one of the other 22 patients with HER2-mutated tumors responded to treatment with pertuzumab plus trastuzumab (biliary cancer).

Patients With BRAF Mutations

Results of treatment with vemurafenib differed markedly in tumors with BRAF V600 mutations when compared with those with other BRAF mutations. Of the 26 patients with BRAF V600 mutations (all V600E), objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%) with six different tumor types (two CR, 10 PR; Table 4). In contrast, only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 1), G496R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.

Fourteen patients had refractory BRAF V600E-mutated non–small-cell lung cancer (adenocarcinoma, n = 13; sarcomatoid, n = 1), composing the largest tumor-pathway cohort in the BRAF group (Table 4). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD at 120 days (Fig 2D). The median DOR was 5 months (range, 4 to 14 months).

All other tumor-pathway cohorts with BRAF V600E mutations were small (four or fewer patients). Assessment of treatment efficacy in these groups is therefore not yet possible.

Patients With Hedgehog Pathway or EGFR Mutations

Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients had PRs to vismodegib (unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1); all three patients had PTCH-1-mutated tumors. Various EGFR mutations were present in the tumors of nine
patients who received erlotinib; one of nine patients (with urethral adenocarcinoma) achieved a PR.

**DISCUSSION**

MyPathway was designed to evaluate the efficacy of targeted treatments in tumors harboring activating molecular alterations in the HER2, BRAF, EGFR, or Hedgehog pathways. In 230 patients who have been treated and evaluated, all four targeted treatments have produced meaningful responses, and 14 different tumor types outside of current US Food and Drug Administration (FDA) indications have responded. Completion of accrual to MyPathway is projected to take an additional 2 to 3 years. We believe that early publication of the encouraging results in several tumor-pathway cohorts will focus attention on these groups and accelerate definitive investigation. In addition, suggestions of activity in other small cohorts may guide the design of additional studies. As a whole, these early results provide further evidence of the feasibility and potential value of the basket study design in defining the optimal use of targeted therapies.

Patients with refractory, metastatic HER2-amplified/overexpressing colorectal cancer composed the largest tumor-treatment group in this study. The incidence of HER2 amplification/overexpression is 2% to 6% in advanced colorectal cancer, accounting for approximately 2,000 patients per year in the United States.25-27 In this study, the 37 patients with colorectal cancer treated with trastuzumab plus pertuzumab had an ORR of 38% (95% CI, 23% to 55%) and a median DOR of 11 months (95% CI, 3 months to not estimable). The response rate and DOR in patients with refractory HER2-amplified/overexpressing colorectal cancer indicate that HER2 is an important driver in this malignancy and compare favorably to the response rates of other drugs recently approved for use in refractory colorectal cancer.28-30 Dual HER2-targeted therapy was also effective in the HER2 Amplification for Colorectal Cancer Enhanced Stratification (HERACLES) trial, in which eight of 27 patients with HER2-amplified/overexpressing, KRAS wild-type metastatic colon cancer (30%) had objective responses to treatment with trastuzumab plus lapatinib.28-30 Results are also encouraging in other HER2-amplified/overexpressing tumor types, including bladder (33% ORR), biliary tract (29% ORR), and salivary gland (80% ORR). Although salivary duct carcinomas are rare, HER2 amplification/overexpression is common in these tumors.31,32 HER2 abnormalities in bladder and biliary cancers occur in 3% to 5% of patients.33,34 New treatment options are urgently needed in all of these treatment-refractory tumor types, and enlargement of these treatment groups is important.

Treatment with vemurafenib had notable activity in patients with refractory BRAF V600E-mutated cancers (46% ORR). In BRAF V600E-mutated NSCLC, treatment efficacy (43% ORR; median DOR, 5 months) was similar to results previously reported in two other basket trials.15,35 In addition to the subsets defined by EGFR, ALK, and ROS-1 alterations, patients with BRAF V600E-mutated NSCLC (approximately 2% of NSCLC36) seem to be an important and targetable NSCLC subset. In contrast, the response rate for patients with non-V600E BRAF mutations was only 4%, and accrual of these patients to MyPathway has been discontinued.

The role of basket trials in identifying patient populations for targeted therapy remains unclear. To date, most basket trials have reported mixed results, which may be due to the pathways being targeted, the methods of molecular testing, or the therapeutic agents being tested. The design of MyPathway maximizes the chance of success by using CLIA-approved molecular testing readily available in the clinic and by selecting FDA-approved targeted agents backed by more than a decade of translational science and clinical experience. Although not all genetic alterations are equally actionable, the four FDA-approved targeted therapies evaluated in MyPathway produced meaningful responses in patients with various tumor types involving well-defined driver alterations.

In conclusion, current results from MyPathway demonstrate potentially clinically meaningful activity for four approved targeted regimens in multiple tumor types harboring specific molecular alterations. Durable responses were seen in patients with colorectal, bladder, biliary, and salivary duct cancers with HER2 activation/overexpression, in patients with NSCLC with BRAF V600E mutations, and in selected patients with PTCH-1/SMO or EGFR alterations. Treatment of additional patients in each of these groups is ongoing to better define the activity of these treatments and to further clarify the importance of molecular and histologic subgroups.

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at jco.org.

**AUTHOR CONTRIBUTIONS**

Conception and design: John D. Hainsworth, Mary Beattie

Provision of study materials or patients: John D. Hainsworth, David R. Spigel

Collection and assembly of data: Bongin Yoo

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**Table 4. Efficacy of Treatment With Vemurafenib in Patients With BRAF V600E-Mutated Cancers**

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>No. of Patients</th>
<th>Response, No. (%)</th>
<th>ORR, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung, non-small-cell</td>
<td>14</td>
<td>1 (7)</td>
<td>2 (14)</td>
</tr>
<tr>
<td>Ovary</td>
<td>4</td>
<td>2 (50)</td>
<td>1 (25)</td>
</tr>
<tr>
<td>Colorectal</td>
<td>2</td>
<td>1 (50)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Thyroid (anaplastic)</td>
<td>1</td>
<td>1 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Head/neck (larynx)</td>
<td>1</td>
<td>1 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other (8 sites)</td>
<td>3</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>2 (8)</td>
<td>10 (38)</td>
</tr>
</tbody>
</table>


Abbreviations: CR, complete response; ORR, objective response rate; PR, partial response; SD, stable disease.
REFERENCES

10. Perjeta (pertuzumab) [prescribing information]. Genentech, South San Francisco, CA; 2016
11. Herceptin (trastuzumab) [prescribing information]. Genentech, South San Francisco, CA; 2016
21. Herceptin (trastuzumab) [prescribing information]. Genentech, South San Francisco, CA; 2014
22. Zelboraf (vemurafenib) [prescribing information]. Genentech, South San Francisco, CA; 2016
23. Zelboraf (vemurafenib) [prescribing information]. Genentech, South San Francisco, CA; 2016
24. Erivedge (vismodegib) [prescribing information]. Genentech, South San Francisco, CA; 2015

Affiliations

John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Ron Bose, Washington University School of Medicine, St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California San Diego, San Diego, CA.

Support

The MyPathway study was supported by Roche/Genentech.

Prior Presentation

Targeted Therapy for Advanced Solid Tumors by Molecular Profile

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/icf.

John D. Hainsworth
Research Funding: Genentech, Novartis, Eli Lilly, AstraZeneca, Astellas Pharma, Johnson & Johnson, Celgene

Funda Meric-Bernstam
Consulting or Advisory Role: Genentech, Infection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health
Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm, Bayer AG, Aileron Therapeutics, PUMA Biotechnology, CytomX Therapeutics, Joune Therapeutics, Zymeworks, Effective Pharmaceuticals, Curis

Charles Swanton
Stock or Other Ownership: Epic Sciences, Apogen Biotechnologies, GRAIL, Achilles Therapeutics
Honoraria: Roche, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Celgene, Ono Pharmaceutical, SERVIER, Pfizer
Consulting or Advisory Role: Genentech
Research Funding: Boehringer Ingelheim

Herbert Hurwitz
Consulting or Advisory Role: Genentech, Bristol-Myers Squibb, Eli Lilly, Novartis, Incyte, TRACON Pharmaceuticals, Acceleron Pharma, GlaxoSmithKline, OncoMed Pharmaceuticals
Research Funding: Genentech, GlaxoSmithKline, Novartis, TRACON Pharmaceuticals, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Eli Lilly, MacroGenics, National Cancer Institute

David R. Spigel
Consulting or Advisory Role: Genentech (Inst), Celgene (Inst), Novartis (Inst), Eli Lilly (Inst), Pfizer (Inst), Bristol-Myers Squibb (Inst), AstraZeneca (Inst)
Research Funding: Genentech (Inst), Pfizer (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), Eli Lilly (Inst), Celgene (Inst)
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Peregrine Pharmaceuticals

Christopher Sweeney
Stock or Other Ownership: Leuchemix
Consulting or Advisory Role: Sanofi, Janssen Biotech, Astellas Pharma, Bayer, Genentech, AstraZeneca, Pfizer
Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Sotio (Inst)
Patents, Royalties, Other Intellectual Property: Leuchemix, Parthenolide, Dimethylaminoparthenolide, Exelixis: Abiraterone plus cabozantinib combination

Howard Burris
Research Funding: Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Tarveda Therapeutics (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), MacroGenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst)

Ron Bose
Honoraria: Genentech, Novartis
Consulting or Advisory Role: Genentech

Bongin Yoo
Employment: Genentech
Stock or Other Ownership: Roche

Alisha Stein
Employment: Genentech
Stock or Other Ownership: Roche

Mary Beattie
Employment: Genentech

Razelle Kurzrock
Stock or Other Ownership: Actuate Therapeutics, CureMatch
Honoraria: Cedars-Sinai, National Comprehensive Cancer Network, American Association for Cancer Research, Yale Cancer Center, XBiotech, Pancreatic Cancer Action Network, Sylvester Cancer Center, Mayo Clinic Cancer Center, Kaiser Permanente, Health Advances, Wiley, Scripps Translational Research Institute, Defined Health, CME Education Resources, Avera Health, Genentech, LOXO Oncology, Health Advances Consulting or Advisory Role: Sequenom, Actuate Therapeutics, XBiotech, Genentech, LOXO Oncology
Research Funding: EMD Serono (Inst), Centocor Ortho Biotech (Inst), GlaxoSmithKline (Inst), Exelixis (Inst), XBiotech, Novartis (Inst), Merck (Inst), Genentech (Inst), Genentech MyPath (Inst), Foundation Medicine (Inst), Pfizer (Inst), Guardant Health (Inst), Sequenom (Inst), Merck Serono (Inst), Incyte
Travel, Accommodations, Expenses: Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine, EMD Serono, Gateway Research Advisory Committee, AACR, Quintiles, Association of American Cancer Institutes, Guardant Health, Global Source Ventures/Novena Therapeutics, American Society for Clinical Pharmacology and Therapeutics, Meyers Consulting, Food and Drug Administration - Orange County Regulatory Affairs, Genentech, Orbimed/Global Source Ventures, Sylvester Cancer Center, Journal of Precision Medicine, CureMatch, Lynx Group, Mayo Clinic Cancer Center, Kaiser Permanente, Pancreatic Cancer Action Network, Cedars-Sinai, MedImmune/JK Associates Medical Communications Group, Federation of the Israel Societies for Experimental Biology, Defined Health
Acknowledgment

We thank the patients, families, clinicians, and study teams who have participated in the MyPathway study. We also thank Melissa Brammer for her contributions to the study and Coen Bernaards, David Moorman, and Bryan Lange for their assistance with the biostatistical analysis. MyPathway was funded by Roche/Genentech. Support for third-party writing assistance was provided by Tiffany DeSimone, of CodonMedical, an Ashfield Company, part of UDG Healthcare, and was funded by Roche/Genentech.